ArticleNature communications2021
Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer.
Hayato Mizuta et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
66 papers cite itlatest 60 shown
this papercites it
ArticleNature communications2021
Hayato Mizuta et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.